STAT3 and hepatocellular carcinoma: Include SMIs, peptide inhibitors, siRNAs, ASOs that interfere with STAT mRNA, and ODNs. Target STAT3, STAT5, as well as STAT dimerization. Phase I clinical trials for treating metastatic CRC, gastric cancer, and HCC